Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

This study has been completed.
Royal University Hospital Foundation
Information provided by:
University of Saskatchewan Identifier:
First received: January 18, 2008
Last updated: January 6, 2009
Last verified: July 2008

Certain lung disease medications can influence diagnostic tests and research investigations. This study will investigate how long ipratropium bromide must be withheld before a methacholine challenge test can be conducted. This information will be useful for validating current guidelines.

Condition Intervention Phase
Drug: ipratropium bromide
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

Resource links provided by NLM:

Further study details as provided by University of Saskatchewan:

Primary Outcome Measures:
  • methacholine PC20 [ Time Frame: 6hours and 12 hours post inhalation ] [ Designated as safety issue: No ]

Enrollment: 12
Study Start Date: January 2008
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: ipratropium bromide
2 puffs (40 micrograms) 2 puffs (0micrograms)
Other Name: Atrovent HFA Inhalation Aerosol
Placebo Comparator: 2 Drug: placebo
Matched placebo


Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of asthma; stable and controlled
  • FEV1 greater than or equal to 65% predicted

Exclusion Criteria:

  • Concomitant lung disease other than asthma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00605410

Canada, Saskatchewan
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N oW8
Sponsors and Collaborators
University of Saskatchewan
Royal University Hospital Foundation
Principal Investigator: Donald W Cockcroft, MD Department of Medicine University of Saskatchewan
  More Information

No publications provided by University of Saskatchewan

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr. Donald W. Cockcroft, Department of Medicine, University of Saskatchewan Identifier: NCT00605410     History of Changes
Other Study ID Numbers: BIO 07-161
Study First Received: January 18, 2008
Last Updated: January 6, 2009
Health Authority: Canada: Health Canada

Keywords provided by University of Saskatchewan:
Methacholine bronchoprovocation

Additional relevant MeSH terms:
Methacholine Chloride
Anti-Asthmatic Agents
Autonomic Agents
Bronchoconstrictor Agents
Bronchodilator Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Agonists
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Agonists
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses processed this record on February 25, 2015